Ottavio De Cobelli1,2, Carlo Buonerba3, Daniela Terracciano4, Danilo Bottero1, Giuseppe Lucarelli5, Pierluigi Bove6, Vincenzo Altieri7, Ioman Coman2, Sisto Perdonà8, Gaetano Facchini9, Massimiliano Berretta10, Giuseppe Di Lorenzo3, Paolo Grieco11, Ettore Novellino11, Renato Franco12, Michele Caraglia13, Claudia Manini14, Vincenzo Mirone15, Sabino De Placido3, Guru Sonpavde16, Matteo Ferro1. 1. Division of Urology, European Institute of Oncology, Milan, Italy. 2. Department of Urology, 'Iuliu Hatieganu' University of Medicine & Pharmacy, Cluj-Napoca, Romania. 3. Oncologia Urologica, Dipartimento di Medicina Clinica e Chirurgia, Azienda Ospedaliera Universitaria 'Federico II', Napoli, Italy. 4. Department of Translational Medical Sciences, University 'Federico II', Naples, Italy. 5. Department of Emergency & Organ Transplantation - Urology, Andrology & Kidney Transplantation Unit, University of Bari, Bari, Italy. 6. Department of Urology, Tor Vergata University of Rome, V.le Oxford 81, Rome, 00133, Italy. 7. Department of Urology of San Giovanni di Dio & Ruggi d'Aragona Hospital, University of Salerno, Salerno, SA, Italy. 8. Department of Urology, National Cancer Institute of Naples, Naples, Italy. 9. Gineco-urological Department, National Cancer Institute of Naples 'Fondazione G Pascale', Naples, Italy. 10. Department of Medical Oncology, National Cancer Institute, Aviano, Italy. 11. Department of Pharmacy, University of Naples, Federico II, Naples 80131, Italy. 12. Pathology Unit, National Cancer Institute 'Fondazione G. Pascale', Naples, Italy. 13. Department of Biochemistry, Biophysics & General Pathology, Second University of Naples, Naples, Italy. 14. Division of Pathology, Giovanni Bosco Hospital, Turin, Italy. 15. Urology Division, University Federico II of Naples, Napoli, Italy. 16. UAB (University of Alabama at Birmingham) Cancer Center, Birmingham, AL 35233, USA.
Abstract
AIM: A higher Gleason score was associated with a lower tumor urotensin II receptor (UTII-R) expression in prostate cancer patients. METHODS: A retrospective review of formalin-fixed paraffin-embedded tumor tissue derived from those who had prostatectomy and matching biopsy specimens was conducted at six Institutions. UTII-R expression was evaluated on biopsy by immunohistochemistry. RESULTS: A total of 58 subjects undergoing radical prostatectomy were included. At multivariate analysis, low UTII-R expression was a significant predictor of Gleason upgrading, with an odds ratio of 10.3 (95% CI: 1.55-68.4), and of pathology upstaging, with an odds ratio of 11.1 (95% CI: 1.23-100.48). CONCLUSIONS: UTII-R expression on biopsy was associated with Gleason upgrading and pathology upstaging in prostate cancer patients.
AIM: A higher Gleason score was associated with a lower tumorurotensin II receptor (UTII-R) expression in prostate cancerpatients. METHODS: A retrospective review of formalin-fixed paraffin-embedded tumor tissue derived from those who had prostatectomy and matching biopsy specimens was conducted at six Institutions. UTII-R expression was evaluated on biopsy by immunohistochemistry. RESULTS: A total of 58 subjects undergoing radical prostatectomy were included. At multivariate analysis, low UTII-R expression was a significant predictor of Gleason upgrading, with an odds ratio of 10.3 (95% CI: 1.55-68.4), and of pathology upstaging, with an odds ratio of 11.1 (95% CI: 1.23-100.48). CONCLUSIONS:UTII-R expression on biopsy was associated with Gleason upgrading and pathology upstaging in prostate cancerpatients.
Entities:
Keywords:
Gleason score; prostate cancer; urotensin II receptor
Authors: Felix K-H Chun; Thomas Steuber; Andreas Erbersdobler; Eike Currlin; Jochen Walz; Thorsten Schlomm; Alexander Haese; Hans Heinzer; Michael McCormack; Hartwig Huland; Markus Graefen; Pierre I Karakiewicz Journal: Eur Urol Date: 2005-12-22 Impact factor: 20.096
Authors: Niall M Corcoran; Matthew K H Hong; Rowan G Casey; Antonio Hurtado-Coll; Justin Peters; Laurence Harewood; S Larry Goldenberg; Chris M Hovens; Anthony J Costello; Martin E Gleave Journal: BJU Int Date: 2011-03-28 Impact factor: 5.588
Authors: Matthew Truong; Jon A Slezak; Chee Paul Lin; Viacheslav Iremashvili; Martins Sado; Aria A Razmaria; Glen Leverson; Mark S Soloway; Scott E Eggener; E Jason Abel; Tracy M Downs; David F Jarrard Journal: Cancer Date: 2013-09-04 Impact factor: 6.860
Authors: John V Hegde; Ming-Hui Chen; Robert V Mulkern; Fiona M Fennessy; Anthony V D'Amico; Clare M C Tempany Journal: Int J Radiat Oncol Biol Phys Date: 2012-10-03 Impact factor: 7.038
Authors: M Demirpence; A Guler; H Yilmaz; A Sayin; Y Pekcevik; H Turkon; A Colak; E M Ari; B Aslanipour; G U Kocabas; M Calan Journal: J Endocrinol Invest Date: 2018-05-26 Impact factor: 4.256
Authors: Matteo Ferro; Daniela Terracciano; Carlo Buonerba; Giuseppe Lucarelli; Danilo Bottero; Sisto Perdonà; Riccardo Autorino; Alessandro Serino; Francesco Cantiello; Rocco Damiano; Iulia Andras; Sabino De Placido; Giuseppe Di Lorenzo; Michele Battaglia; Barbara A Jereczek-Fossa; Vincenzo Mirone; Ottavio De Cobelli Journal: Future Oncol Date: 2016-09-14 Impact factor: 3.404
Authors: Roberto Bianchi; Gabriele Cozzi; Giuseppe Petralia; Sarah Alessi; Giuseppe Renne; Danilo Bottero; Antonio Brescia; Antonio Cioffi; Giovanni Cordima; Matteo Ferro; Deliu Victor Matei; Federica Mazzoleni; Gennaro Musi; Francesco Alessandro Mistretta; Alessandro Serino; Valeria Maria Lucia Tringali; Ioan Coman; Ottavio De Cobelli Journal: Medicine (Baltimore) Date: 2016-10 Impact factor: 1.889
Authors: Simone Flammia; Marco Frisenda; Martina Maggi; Fabio Massimo Magliocca; Antonio Ciardi; Valeria Panebianco; Ettore De Berardinis; Stefano Salciccia; Giovanni Battista Di Pierro; Alessandro Gentilucci; Francesco Del Giudice; Gian Maria Busetto; Michele Gallucci; Alessandro Sciarra Journal: Medicine (Baltimore) Date: 2020-09-18 Impact factor: 1.817